-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy
Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs are still limited, and cytotoxic anticancer drugs are the mainstay of subsequent treatment. In addition, because platinum-based combination therapy is the most successful combination with…
-
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial
In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830-2838. In the SABR-COMET trial,1 random assignment was used to study the effects of ablative therapy in comparison to palliative radiotherapy. However,…
-
Experts Discuss Benefits, Challenges with Lung Cancer Screening: A Pro/Con
Using LDCT to Boost Lung Cancer Prevention Strategies: A Pro/Con By Ugo Pastorino, MD Now we know from robust randomized trials that systematic screening with low-dose computed tomography (LDCT) of the chest can reduce lung cancer mortality in heavy smokers by increasing the proportion of cases detected in an early stage,1,2 when they are amenable…
-
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of the disease and translating this understanding into action by development of new treatments.2 Indeed, since 2015, the United States Food and Drug Administration (FDA) has…
-
Implications of the PACIFIC Trial in 2020
Approximately one-third of patients with NSCLC are diagnosed with stage III disease.1 Concurrent platinum-based chemotherapy with thoracic radiation (CRT) has been considered the cornerstone of treatment for patients with inoperable stage III disease. Consolidation immunotherapy with the PD-L1 inhibitor durvalumab following CRT has revolutionized the treatment paradigm for patients with locally advanced NSCLC and is…
-
Good Communication Strategies While Wearing PPE
Lung cancer care providers have traditionally relied on facial gestures to show empathy. With face coverings now the norm, empathy can actually be shown through improved processes.
-
The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?
IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III non–small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2019;105(2):346-355. The immune system plays critical roles in the pathogenesis,…
-
Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice
Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the RELAY study, which investigated ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced NSCLC.1 In the following interview, Dr. Nakagawa discusses the trial’s results, as…
-
Checkpoint Inhibitors in SCLC: Putting the Most Novel Data in Context
Two separate randomized phase III trials have established atezolizumab (IMpower1331 and durvalumab (CASPIAN2) as first-line treatments for extensive-stage (ES) SCLC in combination with chemotherapy followed by these same checkpoint inhibitors (CPIs) as maintenance on the basis of improvements in OS and PFS outcomes. Hence, the question for clinicians is whether there is a difference between these…
-
Multidisciplinary Tumor Boards: Integrating Best Patient Care and Education in Precision Medicine
One of the pillars of organ-specific tumor centers certified by the German Cancer Society, such as lung, breast, and prostate cancer centers, is a weekly multidisciplinary tumor board (MTD). In our comprehensive cancer center (Center for Integrated Oncology Cologne; CIO), nearly all patients receiving first-line treatment and a substantial portion of patients whose disease has…
View ILCN Archives
Provider Resources
Popular Articles